A Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma (NCT05757102)
A Phase 3, 24-week, Randomized, Double-blind, Parallel-group Bayesian Dynamic Borrowing Study Comparing the Efficacy, Safety, Tolerability and Pharmacokinetics of FF/UMEC/VI With FF/VI in 12-17-year-old Participants With Inadequately Controlled Asthma on Stable Maintenance Therapy With ICS/LABA
🩺 Plain-English Summary (8th-Grade Level)
The primary purpose of this study is to evaluate the effects of Fluticasone Furoate (FF)/ Umeclidinium (UMEC)/ Vilanterol (VI) on lung function compared with FF/VI after 24 weeks of treatment.
Who can join: Review the eligibility criteria below.
Location: GSK Investigational Site — Birmingham, Alabama
Age range: 12 Years to 17 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (62 Sites)
Showing the first 25 of 62 sites.
- GSK Investigational Site — Birmingham, Alabama
- GSK Investigational Site — Mobile, Alabama
- GSK Investigational Site — Paradise Valley, Arizona
- GSK Investigational Site — Bakersfield, California
- GSK Investigational Site — Mission Viejo, California
- GSK Investigational Site — Rolling Hills Estates, California
- GSK Investigational Site — Colorado Springs, Colorado
- GSK Investigational Site — Aventura, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Miami, Florida
- GSK Investigational Site — Savannah, Georgia
- GSK Investigational Site — Normal, Illinois
- GSK Investigational Site — Owensboro, Kentucky
- GSK Investigational Site — Columbia, Missouri
- GSK Investigational Site — Missoula, Montana
- GSK Investigational Site — The Bronx, New York
- GSK Investigational Site — Cincinnati, Ohio
- GSK Investigational Site — Cleveland, Ohio
- GSK Investigational Site — Dayton, Ohio
- GSK Investigational Site — Oklahoma City, Oklahoma
- GSK Investigational Site — Charleston, South Carolina
- GSK Investigational Site — Dallas, Texas
- GSK Investigational Site — Kerrville, Texas
- GSK Investigational Site — Plano, Texas
📞 Contact the Study Coordinator
Phone: (877) 379-3718
Email: GSKClinicalSupportHD@gsk.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Asthma
- Investigating Dupilumab's Effect in Asthma by Genotype — Boston, Massachusetts
- Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma — Bakersfield, California
- Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Saraland, Alabama
- Reduce IDentified UNcontrolled Asthma — San Diego, California
- A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma — Little Rock, Arkansas
- REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study — La Jolla, California
Explore by condition: All Asthma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.